people on the move
Ligand
Ligand, a San Diego company which licences its solubility tech to GSK, Pfizer, Baxter, Lundbeck, Lilly, and Onyx, has a new President.
Matthew Foehr will take on the role after a promotion from Executive VP. He will also remain Chief Operating Officer. Before joining Ligand in 2011, Foehr was Head of Consumer Dermatology R&D in the Stiefel division of GSK. GSK acquired Stiefel in 2009 for $3.6 billion.
Ligand’s Captisol platform is a chemically modified cyclodextrin which lends greater solubility and stability to drugs. The company also develops proprietary therapies.